[18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma.
Peipei Wang, Tuo Li, Zhikai Liu...
https://pubmed.ncbi.nlm.nih.gov/37160439/Actively Recruiting
Early Phase 1
Age: 1Year - 80Years
All Genders
ID05069220
Study of 18F-MFBG PETCT Imaging to Diagnose and Measure Tumor Burden in Pheochromocytoma, Paraganglioma, and Neuroblastoma
Led by Peking Union Medical College Hospital · Updated on 2024-03-01
150
Participants Needed
1
Research Sites
65 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the use of 18F-metafluorobenzylguanidine 18F-MFBG positron emission tomography PET to evaluate neuroendocrine tumors, mainly pheochromocytoma, paraganglioma PPGL, and neuroblastoma NB. These tumors express norepinephrine transporter NET, which is targeted by imaging substances like 123I131I-MIBG. However, current imaging methods have limitations such as low resolution and long waiting times, which affect diagnosis. This study aims to assess the safety, image quality, diagnostic accuracy, and tumor burden detection of 18F-MFBG PET in these neural crest tumors.
CONDITIONS
Brief Title
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Research Team
P
Peipei Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here